Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treasure trove for research and therapy

03.11.2014

They are termed adhesion G protein-coupled receptors. These receptors are involved in a wealth of vital functions in the body and therefore represent a promising target for drugs, yet relatively little is known about how they work. A new research unit is keen to change this.

Seeing, smelling, tasting, when the heart beats, when hormones do their job – during all these processes, and many others, important tasks are undertaken by a certain class of receptors, known as G protein-coupled receptors, or GPCRs for short.


Dr. Tobias Langenhan, head of the new DFG research unit “Elucidation of Adhesion-GPCR Signaling”.

Photo: Gunnar Bartsch

Hundreds of them are encoded in the human genome and sit on the surface of cells, where they receive signals, which they transfer to the cell interior. One indication of their importance is the fact that around half of all clinically approved drugs target these receptors and, in doing so, treat ailments as varied as, for example, hypertension, asthma, and Parkinson’s disease. So, from a scientific perspective, these receptors are “a treasure trove” for the development of new therapeutics.

The new research unit

Adhesion GPCRs form a sub-group of this receptor class. They are the focus of a new research unit that has now been approved by the German Research Foundation (DFG). Its spokesperson is the Würzburg medic and neurobiologist Dr. Tobias Langenhan.

The team includes scientists from the universities of Würzburg, Leipzig, Mainz, Erlangen-Nuremberg, and the Amsterdam Medical Center of the University of Amsterdam. By pooling their expertise in this field it is hoped that they will break new ground together. The DFG will be contributing around two million euros to fund the project over the next three years; an extension of a further three years is possible.

“What do they feel? How do they translate stimuli into a cellular response? And what happens when they are missing?” The scientists involved in the research unit want to find answers to these three questions over the next few years, explains Tobias Langenhan.

There are 33 varieties of adhesion GPCRs in the human body. They are important control centers in the brain and in the immune system; they play a significant role in the development of the heart and blood vessels as well as in other processes. And, although they are among the oldest and largest surface proteins in humans, the way in which they work is still largely a mystery.

When receptors are missing

“We now know a little about what happens when they are missing in certain areas of the body,” says Langenhan. This can cause, for example, the development of Usher syndrome, a common congenital hearing and visual impairment. Or it may lead to a developmental disorder of the brain – “bilateral frontoparietal polymicrogyria”.

Here the cortex folds itself into countless flat gyri; the afflicted suffer from seizures, movement disorders, and retarded mental development. Tumor cells, too, feature faulty adhesion GPCRs, though a causal relationship has yet to be proven in this case. “Fundamental principles of the way in which these receptors work are not yet understood,” says Langenhan. And this is where the work of the new research unit will begin.

Physiology, genetics, pharmacology, biochemistry, structural biology, and pathology: a wide variety of disciplines are represented in the new research unit and will all play their part in shedding light on the signaling behavior of adhesion GPCRs. Developing new drugs is not the primary objective.

“What we do is basic research,” explains Tobias Langenhan. Not until the mechanisms in healthy people are understood can well-founded conclusions be drawn about the pathology, he says. That is not to say, however, that the scientists are completely ignoring any relevance to patients. Langenhan can well envisage the involvement of clinical partners in the potential second period of funding if it goes ahead.

Personal profile

Tobias Langenhan (36) studied medicine at the University of Würzburg from 1997 to 2004. In 2006, he received a doctorate from the Institute of Anatomy with a thesis in neuroanatomy. From 2004 to 2009, Langenhan studied for a Master’s degree and a doctorate at the University of Oxford on a full scholarship from the Wellcome Trust. It was during his doctorate there that he first turned his attention to the way in which adhesion GPCRs work. Since 2009, he has acted as group leader at the Department of Physiology (focus on neurophysiology) at the University of Würzburg.

Contact

Dr. Tobias Langenhan, MSc DPhil (Oxon), T: +49 (0)931 31-88681, tobias.langenhan@uni-wuerzburg.de

DFG research units
A research unit is made up of a team of researchers working together on a research project, according to the DFG’s website. The objective behind supporting research units is to help provide the necessary staff and material resources for close collaboration, usually over six years. Research units often contribute to the establishment of new research directions.

Gunnar Bartsch | Julius-Maximilians-Universität Würzburg
Further information:
http://www.uni-wuerzburg.de

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>